Development of vaccines for Marburg hemorrhagic fever

Daniel G. Bausch, Thomas Geisbert

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.

Original languageEnglish (US)
Pages (from-to)57-74
Number of pages18
JournalExpert Review of Vaccines
Volume6
Issue number1
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Marburg Virus Disease
Ebolavirus
Disease Outbreaks
Vaccines
Marburgvirus
Angola
Central Africa
Democratic Republic of the Congo
Vesicular Stomatitis
Primates
Antiviral Agents
Fever
Viruses
Mortality
Infection

Keywords

  • Filoviridae
  • Filovirus
  • Marburg hemorrhagic fever
  • Marburg virus
  • Pathogenesis
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Development of vaccines for Marburg hemorrhagic fever. / Bausch, Daniel G.; Geisbert, Thomas.

In: Expert Review of Vaccines, Vol. 6, No. 1, 02.2007, p. 57-74.

Research output: Contribution to journalArticle

@article{91c78b052188476dbe4f36a5cc4435ac,
title = "Development of vaccines for Marburg hemorrhagic fever",
abstract = "Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90{\%} dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.",
keywords = "Filoviridae, Filovirus, Marburg hemorrhagic fever, Marburg virus, Pathogenesis, Vaccines",
author = "Bausch, {Daniel G.} and Thomas Geisbert",
year = "2007",
month = "2",
doi = "10.1586/14760584.6.1.57",
language = "English (US)",
volume = "6",
pages = "57--74",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Development of vaccines for Marburg hemorrhagic fever

AU - Bausch, Daniel G.

AU - Geisbert, Thomas

PY - 2007/2

Y1 - 2007/2

N2 - Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.

AB - Marburg (MARV) and Ebola viruses (EBOV) emerged from the rainforests of Central Africa more than 30 years ago causing outbreaks of severe and, usually, fatal hemorrhagic fever. EBOV has garnered the lion's share of the attention, fueled by the higher frequency of EBOV outbreaks, high mortality rates and importation into the USA, documented in such popular works as the best-selling novel 'The Hot Zone'. However, recent large outbreaks of hundreds of cases of MARV infection in the Democratic Republic of the Congo and Angola with case fatalities approaching 90% dramatically highlight its lethal potential. Although no vaccines or antiviral drugs for MARV are currently available, remarkable progress has been made over the last few years in developing potential countermeasures against MARV in nonhuman primate models. In particular, a vaccine based on attenuated recombinant vesicular stomatitis virus was recently shown to have both preventive and postexposure efficacy.

KW - Filoviridae

KW - Filovirus

KW - Marburg hemorrhagic fever

KW - Marburg virus

KW - Pathogenesis

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=33846916219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846916219&partnerID=8YFLogxK

U2 - 10.1586/14760584.6.1.57

DO - 10.1586/14760584.6.1.57

M3 - Article

VL - 6

SP - 57

EP - 74

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 1

ER -